References
Rider JR, Trinquart L. Observational studies have a critical role to play in cancer comparative effectiveness research. J Clin Oncol. 2019;37(29):2695–6. https://doi.org/10.1200/JCO.19.01043.
Schmitz JJ, Schmit GD, Atwell TD, et al. Percutaneous cryoablation of extraabdominal desmoid tumors: a 10-year experience. AJR Am J Roentgenol. 2016;207(1):190–5. https://doi.org/10.2214/AJR.15.14391.
Kasper B, Baumgarten C, Garcia J, et al. An update on the management of sporadic desmoid-type fibromatosis: a European consensus initiative between sarcoma patients euronet (SPAEN) and european organization for research and treatment of cancer (EORTC)/soft tissue and bone sarcoma group (STBSG). Ann Oncol. 2017;28(10):2399–408. https://doi.org/10.1093/annonc/mdx323.
Gronchi A, Miah AB, Dei Tos AP, et al 2021 Electronic address: clinicalguidelines@esmo.org. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 32:S0923–7534(21)02184–0. https://doi.org/10.1016/j.annonc.2021.07.006.
Kurtz JE, Buy X, Deschamps F, et al. CRYODESMO-O1: a prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. Eur J Cancer. 2021;143:78–87. https://doi.org/10.1016/j.ejca.2020.10.035.
Funding
This study was not supported by any funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Fees for oral presentation from Boston Scientific, Canon Medical, Medtronic, Johnson & Johnson.
Ethical Approval
For this type of study formal consent is not required.
Informed Consent
For this type of study informed consent is not required.
Consent for Publication
For this type of study consent for publication is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Garnon, J. No More Technicians in the Shadows: Bringing Interventional Oncology into the Light of Multidisciplinary Tumor Boards. Cardiovasc Intervent Radiol 45, 152–153 (2022). https://doi.org/10.1007/s00270-021-02997-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-021-02997-w